|
Malpuech facial clefting syndrome
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
COLEC10 is mutated in 3MC patients and regulates early craniofacial development.
|
28301481 |
2017 |
|
Malpuech facial clefting syndrome
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
COLEC10 is mutated in 3MC patients and regulates early craniofacial development.
|
28301481 |
2017 |
|
Malpuech facial clefting syndrome
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome.
|
21258343 |
2011 |
|
Malpuech facial clefting syndrome
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Malpuech facial clefting syndrome
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Craniofacial ulnar renal syndrome
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
COLEC10 is mutated in 3MC patients and regulates early craniofacial development.
|
28301481 |
2017 |
|
Basal cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
|
31174203 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found GPR56 and CLL-1 to be the most prominently differently expressed surface markers in AML subcompartments.
|
30848055 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that CLL-1 shares similar prevalence and trafficking properties that make CD33 an excellent ADC target for AML, but lacks expression on hematopoietic stem cells that hampers current CD33-targeted ADCs.
|
29959143 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
|
31055076 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this paper, we will review the expression of CLL-1 on normal cells and AML, the value of CLL-1 in diagnosis and follow-up, and targeting CLL-1 therapy-based antibody and chimeric antigen receptor T cell therapy as well as providing an overview of CLL-1 as a target for AML.
|
31014360 |
2019 |
|
Basal Cell Neoplasm
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
|
31174203 |
2019 |
|
Childhood asthma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Architectures of Childhood- and Adult-Onset Asthma Are Partly Distinct.
|
30929738 |
2019 |
|
Basal Cell Cancer
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
|
31174203 |
2019 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.
|
29304378 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
CLL-1 CAR-T represents a promising immunotherapy for the treatment of AML.
|
29316944 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additional antigenic targets of interest in AML include CLL1, CD38, CD25, TIM3, FLT3, and others.
|
29206680 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that CLL1-ADC could be an effective ADC therapeutic for the treatment of AML.
|
30037800 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, in a disseminated mouse xenograft model using the CLL1-positive HL60 cell line, these CAR-T-cells completely eradicated tumor, thus supporting CLL1 as a promising target for CAR-T-cells to treat AML while limiting myelosuppressive toxicity.
|
29077054 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe the development and evaluation of CLL-1-specific chimeric antigen receptor T cells (CLL-1.CAR-Ts) and we demonstrate their specific activity against CLL-1<sup>+</sup> AML cell lines as well as primary AML patient samples in vitro.
|
28676343 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34<sup>+</sup> Acute Myeloid Leukemia.
|
28810819 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
CLL-1 is prevalent in AML and, unlike other targets such as CD33 and CD123, is not expressed on hematopoietic stem cells providing potential hematopoietic recovery.
|
27908880 |
2017 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density.
|
24249740 |
2014 |